About CareDx (NASDAQ:CDNA)
CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CDNA
CUSIPN/A
Phone415-287-2300
Debt
Debt-to-Equity Ratio-3.08%
Current Ratio0.62%
Quick Ratio0.50%
Price-To-Earnings
Trailing P/E Ratio-12.30
Forward P/E Ratio-21.91
P/E GrowthN/A
Sales & Book Value
Annual Sales$48.32 million
Price / Sales5.67
Cash FlowN/A
Price / CashN/A
Book Value($0.21) per share
Price / Book-44.86
Profitability
EPS (Most Recent Fiscal Year)($0.77)
Net Income$-55,460,000.00
Net Margins-114.79%
Return on Equity-349.65%
Return on Assets-22.88%
Miscellaneous
Employees179
Outstanding Shares29,080,000
CareDx (NASDAQ:CDNA) Frequently Asked Questions
What is CareDx's stock symbol?
CareDx trades on the NASDAQ under the ticker symbol "CDNA."
How were CareDx's earnings last quarter?
CareDx (NASDAQ:CDNA) posted its earnings results on Thursday, March, 22nd. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.06. The business had revenue of $12.50 million for the quarter, compared to analyst estimates of $12.09 million. CareDx had a negative return on equity of 349.65% and a negative net margin of 114.79%. View CareDx's Earnings History.
When is CareDx's next earnings date?
What price target have analysts set for CDNA?
4 equities research analysts have issued twelve-month price targets for CareDx's shares. Their predictions range from $6.50 to $12.00. On average, they anticipate CareDx's share price to reach $8.8750 in the next twelve months. View Analyst Ratings for CareDx.
Are investors shorting CareDx?
CareDx saw a decline in short interest during the month of March. As of March 29th, there was short interest totalling 1,164,799 shares, a decline of 78.4% from the March 15th total of 5,387,444 shares. Based on an average daily trading volume, of 889,989 shares, the days-to-cover ratio is presently 1.3 days. Currently, 6.3% of the company's stock are sold short.
Who are some of CareDx's key competitors?
Some companies that are related to CareDx include RadNet (RDNT), Natera (NTRA), Invitae (NVTA), Enzo Biochem (ENZ), Veracyte (VCYT), Miragen Therapeutics (MGEN), Celcuity (CELC), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), Biocept (BIOC), OpGen (OPGN), Cord Blood America (CBAI) and PotNetwork (POTN).
Who are CareDx's key executives?
CareDx's management team includes the folowing people:
- Michael D. Goldberg, Independent Chairman of the Board (Age 59)
- Peter Maag Ph.D., President, Chief Executive Officer, Director (Age 49)
- Michael Bell, Chief Financial Officer
- Mitchell J. Nelles Ph.D., Chief Operating Officer (Age 62)
- John J. Sninsky Ph.D., Chief Scientific Officer (Age 65)
- Josh DeFonzo, Chief Commercial Officer (Age 34)
- Matthew J. Meyer, Chief Business Officer (Age 46)
- James P. Yee M.D., Ph.D., Chief Medical Officer
- George W. Bickerstaff III, Independent Director (Age 62)
- Fred E. Cohen Ph.D. M.D., Independent Director (Age 60)
Has CareDx been receiving favorable news coverage?
News articles about CDNA stock have trended somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CareDx earned a media sentiment score of 0.10 on Accern's scale. They also gave media stories about the company an impact score of 44.33 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of CareDx?
Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CareDx's stock price today?
One share of CDNA stock can currently be purchased for approximately $9.42.
How big of a company is CareDx?
CareDx has a market capitalization of $271.85 million and generates $48.32 million in revenue each year. The company earns $-55,460,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis. CareDx employs 179 workers across the globe.
How can I contact CareDx?
CareDx's mailing address is 3260 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The company can be reached via phone at 415-287-2300 or via email at [email protected]
MarketBeat Community Rating for CareDx (CDNA)
MarketBeat's community ratings are surveys of what our community members think about CareDx and other stocks. Vote "Outperform" if you believe CDNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
CareDx (NASDAQ:CDNA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for CareDx in the last 12 months. Their average twelve-month price target is $8.8750, suggesting that the stock has a possible downside of 5.79%. The high price target for CDNA is $12.00 and the low price target for CDNA is $6.50. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $8.8750 | $8.8750 | $8.8750 | $7.8333 |
| Price Target Upside: | 5.79% downside | 48.41% upside | 32.46% upside | 39.38% upside |
CareDx (NASDAQ:CDNA) Consensus Price Target History
CareDx (NASDAQ:CDNA) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
CareDx (NASDAQ:CDNA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
CareDx (NASDAQ CDNA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.40%
Institutional Ownership Percentage: 51.50%
CareDx (NASDAQ CDNA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/27/2018 | Peter Maag | Insider | Sell | 15,000 | $7.87 | $118,050.00 | 272,037 |  |
| 12/8/2017 | James P Yee | Insider | Sell | 29,197 | $7.00 | $204,379.00 | 74,795 | |
| 11/30/2017 | Mitchell J Nelles | COO | Sell | 10,948 | $7.17 | $78,497.16 | 84,225 | |
| 10/5/2017 | Neil Gagnon | Major Shareholder | Buy | 10,642 | $4.00 | $42,568.00 | | |
| 9/7/2017 | Neil Gagnon | Major Shareholder | Buy | 6,496 | $3.05 | $19,812.80 | 916,546 | |
| 8/28/2017 | Neil Gagnon | Major Shareholder | Buy | 21,448 | $2.77 | $59,410.96 | 903,731 | |
| 8/25/2017 | Neil Gagnon | Major Shareholder | Buy | 35,119 | $2.92 | $102,547.48 | 890,473 | |
| 8/15/2017 | Michael Brian Bell | CFO | Buy | 725 | $1.83 | $1,326.75 | 375 | |
| 8/15/2017 | Peter Maag | Insider | Buy | 600 | $1.82 | $1,092.00 | 107,350 | |
| 7/24/2017 | Neil Gagnon | Major Shareholder | Buy | 1,486 | $1.23 | $1,827.78 | 886,216 | |
| 6/29/2017 | Neil Gagnon | Major Shareholder | Buy | 1,808 | $1.11 | $2,006.88 | 886,216 | |
| 6/23/2017 | Neil Gagnon | Major Shareholder | Buy | 63,120 | $1.10 | $69,432.00 | 886,216 | |
| 5/24/2017 | Neil Gagnon | Major Shareholder | Buy | 7,439 | $1.00 | $7,439.00 | 879,914 | |
| 5/23/2017 | Neil Gagnon | Major Shareholder | Buy | 6,836 | $1.04 | $7,109.44 | 878,777 | |
| 4/28/2017 | Neil Gagnon | Major Shareholder | Buy | 15,116 | $0.89 | $13,453.24 | 873,928 | |
| 3/16/2017 | Neil Gagnon | Major Shareholder | Buy | 123,160 | $1.83 | $225,382.80 | 778,133 | |
| 9/22/2016 | Neil Gagnon | Major Shareholder | Buy | 178,686 | $4.00 | $714,744.00 | 613,473 | |
| 4/14/2016 | Neil Gagnon | Major Shareholder | Buy | 93,240 | $4.02 | $374,824.80 | 419,638 | |
| 10/21/2015 | Neil Gagnon | major shareholder | Buy | 1,431 | $4.99 | $7,140.69 | 1,243,852 | |
| 10/20/2015 | Neil Gagnon | Major Shareholder | Buy | 1,347 | $4.92 | $6,627.24 | 1,242,421 | |
| 9/29/2015 | Neil Gagnon | major shareholder | Buy | 6,332 | $6.10 | $38,625.20 | 1,240,886 | |
| 9/4/2015 | Neil Gagnon | Major Shareholder | Buy | 69,383 | $6.95 | $482,211.85 | | |
| 6/5/2015 | Neil Gagnon | Major Shareholder | Buy | 6,500 | $5.69 | $36,985.00 | | |
| 6/1/2015 | Peter Maag | CEO | Buy | 2,000 | $4.84 | $9,680.00 | | |
| 4/17/2015 | Neil Gagnon | Major Shareholder | Buy | 13,051 | $5.34 | $69,692.34 | | |
| 3/20/2015 | Neil Gagnon | Major Shareholder | Buy | 6,324 | $6.35 | $40,157.40 | | |
| 2/27/2015 | Neil Gagnon | Major Shareholder | Buy | 4,270 | $6.03 | $25,748.10 | | |
| 2/6/2015 | Neil Gagnon | Major Shareholder | Buy | 4,586 | $7.20 | $33,019.20 | | |
| 2/5/2015 | Neil Gagnon | Major Shareholder | Buy | 121,587 | $7.10 | $863,267.70 | | |
| 2/4/2015 | Neil Gagnon | Major Shareholder | Buy | 31,991 | $7.00 | $223,937.00 | | |
| 2/3/2015 | Neil Gagnon | Major Shareholder | Buy | 23,558 | $7.03 | $165,612.74 | | |
| 2/2/2015 | Neil Gagnon | Major Shareholder | Buy | 3,620 | $7.05 | $25,521.00 | | |
| 1/29/2015 | Neil Gagnon | Major Shareholder | Buy | 15,395 | $7.04 | $108,380.80 | | |
| 1/27/2015 | Neil Gagnon | Major Shareholder | Buy | 84,720 | $7.00 | $593,040.00 | | |
| 1/22/2015 | Neil Gagnon | Major Shareholder | Buy | 48,670 | $7.13 | $347,017.10 | | |
| 1/20/2015 | Neil Gagnon | Major Shareholder | Buy | 16,192 | $6.66 | $107,838.72 | | |
| 1/15/2015 | Neil Gagnon | Major Shareholder | Buy | 39,109 | $6.43 | $251,470.87 | | |
| 1/14/2015 | Neil Gagnon | Major Shareholder | Buy | 122,319 | $7.07 | $864,795.33 | | |
| 7/22/2014 | Ken Ludlum | CFO | Buy | 7,000 | $10.00 | $70,000.00 | | |
| 7/22/2014 | Michael Goldberg | Director | Buy | 25,000 | $10.00 | $250,000.00 | | |
| 7/22/2014 | Perkins Caufield & Bye Kleiner | Major Shareholder | Buy | 52,770 | $10.00 | $527,700.00 | | |
(Data available from 1/1/2013 forward)
CareDx (NASDAQ CDNA) News Headlines
| Source: |
|
CareDx (NASDAQ:CDNA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
CareDx (NASDAQ:CDNA) Income Statement, Balance Sheet and Cash Flow Statement
CareDx (NASDAQ CDNA) Stock Chart for Thursday, April, 26, 2018
Loading chart…
